Silo Pharma, Inc. - Common Stock (SILO)

Silo Pharma (NASDAQ: SILO) commented on a series of coordinated U.S. federal actions accelerating the development of psychedelic-based therapies for mental health and substance use disorders, citing new funding initiatives, clinical progress and regulatory advancements. The company pointed to programs from agencies including ARPA-H and the FDA, such as IND clearance for a noribogaine candidate and the issuance of priority vouchers to leading organizations, as signals of growing institutional support and increased clarity expected to drive innovation in treating conditions such as PTSD and addiction.

Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment

Silo Pharma (NASDAQ: SILO) announced a strategic expansion into artificial intelligence as a second line of business following its acquisition of assets from Qwikagents.ai, a platform designed to deploy autonomous AI agents for tasks including research, content generation, scheduling and workflow automation. The company said the move positions it to capitalize on a rapidly growing AI agent market projected to reach $47 billion to $53 billion by 2030, while it continues advancing its SPC-15 PTSD program toward an investigational new drug application submission and Phase 1 clinical trials, underscoring a dual focus on biopharmaceutical development and emerging AI-driven revenue opportunities.

Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1

SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, announced that the European Patent Office has issued a Rule 71(3) communication indicating its intent to grant a patent covering methods of preventing stress-induced fear and depressive-like behavior using serotonin 4 (5-HT4) receptor agonists. The patent, exclusively licensed from Columbia University, is expected to strengthen the company’s intellectual property position across major European markets as Silo advances its pipeline targeting stress-related and central nervous system disorders.

EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio

Silo Pharma (NASDAQ: SILO) announced that its board of directors authorized a share repurchase program to acquire up to $1 million of the company’s common stock. Purchases may occur on the open market, through privately negotiated transactions or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. The company reported 13,318,273 shares of common stock outstanding as of Nov. 13, 2025, according to its quarterly report for the period ended Sept. 30, 2025. The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations, and the program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion.

Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements.   The Company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as reported in its Quarterly Report for the period ended September 30, 2025.

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal therapeutic targeting post-traumatic stress disorder. The application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior,” includes composition and method claims and expands Silo’s intellectual property portfolio in stress-modulating therapeutics within a key international market, with management noting the allowance supports protection of the Company’s core scientific innovations ahead of formal patent grant.

Patent strengthens protection for novel PTSD drug and advances the Company’s international IP strategy

Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety